Assessing the impact of discontinuation of formulary prior authorization on antibiotic prescribing.


Journal

Antimicrobial stewardship & healthcare epidemiology : ASHE
ISSN: 2732-494X
Titre abrégé: Antimicrob Steward Healthc Epidemiol
Pays: England
ID NLM: 9918266096106676

Informations de publication

Date de publication:
2024
Historique:
received: 26 02 2024
revised: 24 04 2024
accepted: 25 04 2024
medline: 30 9 2024
pubmed: 30 9 2024
entrez: 30 9 2024
Statut: epublish

Résumé

To compare prescribing patterns of restricted antimicrobials before and after the removal of prior authorization and to develop a prospective audit and feedback program to mitigate the potential inappropriate prescribing of these antimicrobials. An interrupted time-series analysis assessing the trends in antibiotic use was conducted between May 2020 and February 2023 in large urban hospitals, where all ASP activities were discontinued in May 2022 and a pilot prospective audit and feedback (PAF) program was initiated in January 2023. The collective change in restricted antibiotic utilization after the removal of prior authorization was trending towards increased utilization but was not statistically significant. With the PAF program, 9.8% of patients were identified by the antimicrobial stewardship pharmacists as requiring intervention. Within these patients, 19 different recommendations were made, with the most common being to narrow the therapeutic spectrum (47.4%). Stewardship interventions suggestions were accepted (full and partial) 69.2% of the time. Although there were some small statistically significant changes detected for a few antibiotics, there were no situations where those changes remained significant after appropriate controls were added to the analyses. As such, the intervention may not have had any statistically significant impact on DDDs of the studied antibiotics.

Identifiants

pubmed: 39346663
doi: 10.1017/ash.2024.92
pii: S2732494X24000925
pmc: PMC11427963
doi:

Types de publication

Journal Article

Langues

eng

Pagination

e150

Informations de copyright

© The Author(s) 2024.

Déclaration de conflit d'intérêts

The authors declare that they have no competing interests or disclosures.

Auteurs

Teagan Zeggil (T)

Alberta Health Services, Edmonton, AB, Canada.

Tony Nickonchuk (T)

Drug Utilization and Stewardship Pharmacist, Alberta Health Services, Edmonton, AB, Canada.

Elissa Rennert-May (E)

Division of Infectious Diseases, Department of Medicine, Foothills Medical Center, Calgary, AB, Canada.

Irina Rajakumar (I)

Pharmacy Clinical Practice Leader, Alberta Health Services, Calgary, AB, Canada.

Classifications MeSH